Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Fresenius Medical Profit Rises on Dialysis Demand

Don't Miss Out —
Follow us on:

May 4 (Bloomberg) -- Fresenius Medical Care AG, the world’s biggest provider of kidney dialysis, reported a higher first-quarter profit on increased demand for blood cleansing services.

Profit rose 7 percent to $211 million, the Bad Homburg, Germany-based company said today in a statement. Sales increased 13 percent to $2.88 billion. Earnings fell short of the average estimate of $214 million from 5 analysts surveyed by Bloomberg.

Fresenius reiterated that it expects profit growth of as much as 10 percent this year to between $950 million and $980 million, compared with $891 million in 2009, and revenue of more than $12 billion. The company has said it’s doubling the budget for acquisitions to as much as $400 million this year as pressure on health costs creates opportunities for deals at attractive prices.

“Strong organic growth is expected to continue and we also expect to strengthen our global presence through selective acquisitions, especially in the area of dialysis services,” Chief Executive Officer Ben Lipps said in the statement.

Fresenius shares fell 0.4 percent to 40.94 euros in Frankfurt trading. The stock has gained 11 percent this year.

Treatment Revenue

Fresenius’s sales in North America, its largest market, rose 10 percent to $1.96 billion. Average revenue per treatment in the region increased to $355 in the first quarter from $338 a year earlier, helped by higher reimbursement rates. Average revenue per treatment was $357 in the fourth quarter of 2009.

The company has said it faces changes as the U.S. introduces a bundled pricing system in 2011 to cap fees for dialysis at about $250 for each treatment for Medicare patients.

Parent company Fresenius SE reported first-quarter profit including special items of 119 million euros ($157 million), an increase of 8 percent from last year, and reiterated that it expects sales to increase between 7 percent and 9 percent. Profit including special items should rise between 8 percent and 10 percent, the company said.

Fresenius, also based in Bad Homburg, operates private hospital operator Helios and the Vamed services unit; Fresenius Kabi, which sells infusion therapies and clinical nutrition; and a biotechnology unit.

To contact the reporter on this story: Dermot Doherty in Geneva at ddoherty9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.